Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 7/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ESRRB | O95718 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066768 | 0.81 | CNR2 (0.51) | NPC1RAB9A | |
| SCHEMBL4607184 | 0.81 | CNR2 (0.51) | NPC1RAB9A | |
| SCHEMBL23201144 | 0.81 | CNR2 (0.51) | NPC1RAB9A | |
| SCHEMBL6308451 | 0.78 | MMP1 (0.42) | NR1H4 | |
| SCHEMBL5336601 | 0.74 | RECQL (0.45) | ESRRGSLC13A5ESRRBGRIA4RECQL | |
| SCHEMBL1596656 | 0.73 | MAPK1 (0.48) | EPHX2NPC1RAB9AACACB | |
| SCHEMBL11828934 | 0.73 | ESRRG (0.49) | ESRRGNR1H4EPHX2SLC13A5NPC1 | |
| SCHEMBL22651514 | 0.73 | ESRRG (0.49) | ESRRGNR1H4EPHX2SLC13A5NPC1 | |
| SCHEMBL16384160 | 0.73 | PPARA (0.50) | — | |
| SCHEMBL5018566 | 0.72 | HDAC1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007047575-A2 | PHARMACOLOGICAL TREATMENTS FOR SLEEP-RELATED BREATHING DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-26 | — | — | WO | disclosed |
| US-6872748-B2 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | DIGITAL BIOTECH CO., LTD. (KR) | 2005-03-29 | — | — | US | disclosed |
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | MEDIFRON DBT CO., LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
| WO-2003027064-A1 | SIMPLIFIED RESINIFERATOXIN ANALOGUES AS VANILLOID RECEPTOR AGONIST SHOWING EXCELLENT ANALGESIC ACTIVITY AND THE PHARMACEUTICAL CO MPOSITIONS CONTAINING THE SAME | DIGITAL BIOTECH CO. LTD,. (KR) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063786-A1 | Simplified resiniferatoxin analogues as vanilloid receptor agonist showing excellent analgesic activity and the pharmaceutical compositions containing the same | TRPV1, OPRL1, GPR180 | ESRRG 384/4885NR1H4 509/4885EPHX2 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.